Pfizer reports revenue miss, weaker than expected COVID-19 vaccine sales forecast

 JULIE HYMAN: First, we've got to talk about Pfizer and its numbers this morning because there too, we saw a disappointment. The shares are off by 4%. And the disappointment is in the revenue.

So you can see a little bit there. It's also in the forecast for 2022 sales and profit forecasts from Pfizer, missing analysts' estimates.

And what's interesting here is, it's the vaccine for COVID-19 and Pfizer's treatment that seemed to be the core of that disappointment, which is definitely a surprise here because Pfizer has been obviously selling so much of it.

We could point out as well that the stock decline this morning is coming on the back of what has been strong performance from Pfizer.

BRIAN SOZZI: Yeah, I know we always tend to-- you know, the market always looks-- as they say-- for, Julie, and it's always concerned with growth rates. I understand there might be some disappointment here.

But take a step back, here, you have Pfizer outlining this year, potentially, $102 billion in total sales. Last year, they had $81.3 billion. Their earnings outlook-- our earnings outlook is about $2 per share higher than what they produced last year.

So again, this company continues to drive major sales, major earnings. It's not just because of the COVID-19 vaccine. They're selling-- they're in leadership positions in many other markets here.

Understand the disappointment, but I would encourage investors to keep in mind just the-- the growth this company is putting up on top of very large numbers from last year. It's very impressive.

JULIE HYMAN: True, but that-- that $102 billion-- as large as it is-- analysts, apparently, were looking for $4 billion more. So there you go.

https://finance.yahoo.com/video/pfizer-reports-revenue-miss-weaker-144334926.html